Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
How has the acute care syndromic testing market size evolved in recent years?
In the past few years, there has been a swift expansion in the size of the acute care syndromic testing market. Indeed, it is projected to augment from a value of $4.08 billion in 2024 to $4.62 billion in 2025, signaling a compound annual growth rate (CAGR) of 13.2%. This significant surge during the historical period can be credited to factors such as heightened awareness about antimicrobial resistance, augmented government budget allocation to fight infectious ailments, increased investment in healthcare infrastructure, and an elevated emphasis on syndromic testing. Additionally, the extension of telemedicine services and a surge in infectious diseases have also contributed to this growth.
What are the predictions for the acute care syndromic testing market size in the coming years?
In the upcoming years, it is anticipated that the market size for acute care syndromic testing will experience rapid expansion. The market is projected to escalate to $7.50 billion by 2029, with a 12.9% compound annual growth rate (CAGR). This progress during the forecast period can be credited to the increasing instances of infectious diseases, a heightened need for quicker diagnostic solutions, the broadening of healthcare services, the rising utilization of multiplex syndromic panels and an expanding geriatric demographic. The forecast period also points towards significant trends such as the move towards point-of-care testing, the incorporation of cloud-based platforms, the uptake of multiplex panels, the evolution of AI-enabled tools, and the introduction of automation into syndromic testing.
Get your acute care syndromic testing market report here!
https://www.thebusinessresearchcompany.com/report/acute-care-syndromic-testing-global-market-report
What key factors are fueling the growth of the acute care syndromic testing market?
The acute care syndromic testing market is anticipated to be driven by the rising occurrence of infectious diseases. These diseases, caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites, can easily spread amongst humans, animals, or from the environment. Several factors are contributing to the surging occurrence of these diseases, including population growth, antimicrobial resistance, urbanization, global travel, and climate change, thereby enhancing the demand for effective prevention and treatment techniques. Acute care syndromic testing plays a crucial role in managing infectious diseases by identifying pathogens and co-infections quickly through extensive molecular diagnostics, which enables precise treatment plans. For instance, the Health Security Agency, based in the UK, reported in February 2024 that the influenza positivity rate in the fourth week of 2024 rose to 16.6%, a sharp rise from the preceding week’s 14.0%. The agency also highlighted that consultations for influenza-like illness (ILI) increased, hitting 9.8 per 100,000 people in contrast to the previous week’s 7.5 per 100,000. Hospitalization due to influenza also grew to 7.63 per 100,000, a substantial rise from the earlier week’s 5.12 per 100,000. Thus, the escalating prevalence of infectious diseases is propelling the growth of the acute care syndromic testing market.
How is the global acute care syndromic testing market divided into key segments?
The acute care syndromic testing market covered in this report is segmented –
1) By Disease Type: Respiratory Diseases, Gastrointestinal Diseases, Genitourinary Diseases, Tropical Diseases, Other Disease Types
2) By Sample Type: Blood, Urine, Biofluids, Stool, Swabs, Other Sample Types
3) By Target: Bacteria, Viruses, Fungi, Parasites
4) By End User: Hospitals, Clinical And Diagnostic Laboratories, Research And Academic Institutions, Other End Users
Subsegments:
1) By Respiratory Diseases: Influenza, Respiratory Syncytial Virus (RSV), COVID-19, Tuberculosis, Other Respiratory Diseases
2) By Gastrointestinal Diseases: Clostridium Difficile Infection, Norovirus, Rotavirus, Salmonella, Other Gastrointestinal Diseases
3) By Genitourinary Diseases: Urinary Tract Infections (UTIs), Sexually Transmitted Infections (STIs), Vaginal Infections, Other Genitourinary Diseases
4) By Tropical Diseases: Malaria, Dengue, Chikungunya, Zika Virus, Other Tropical Diseases
5) By Other Disease Types: Meningitis, Sepsis, Other Emerging Infectious Diseases
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21078&type=smp
Who are the key firms paving the way for growth in the acute care syndromic testing market?
Major companies operating in the acute care syndromic testing market are Siemens Healthineers AG, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Danaher Corporation, Becton, Dickinson and Company, Seegene Inc., bioMérieux SA, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Werfen, DiaSorin S.p.A., Quidel Corporation, Luminex Corporation, Biocartis NV, Microbiologics Inc., QuantuMDx Group Ltd., Curetis GmbH by OpGen Inc., Genetic Signatures Ltd., Applied BioCode Inc.
What key trends are currently impacting the acute care syndromic testing market’s development?
Prominent firms involved in the acute care syndromic testing market are placing an emphasis on technology advancements such as multiplex real-time polymerase chain reaction (PCR) technology to uplift diagnostic accuracy, expedite the detection of pathogens, streamline workflows in laboratories, cut down on response time, and boost patient results through accurate and timely treatments. The multiplex real-time PCR technology is an advanced diagnostic technique at the molecular level that can identify and measure multiple pathogens or genetic targets at once during a single PCR reaction, thereby boosting efficiency and precision in diagnosing diseases. For instance, in April 2023, QIAGEN N.V., a biotechnology research company based in the Netherlands, brought the QIAstat-Dx syndromic testing solution to Japan. This included a SARS-CoV-2 respiratory panel capable of identifying over 20 pathogens in one sample. Utilising the multiplex real-time PCR technology, it offers quick results with less effort than individual PCR assays. By the close of 2022, over 3,500 systems had been installed globally, aiding in diagnosing respiratory, gastrointestinal, and meningitis-related ailments. Available in above 100 countries, the system is increasing access to syndromic testing around the world.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21078
What regions are contributing significantly to the growth of the acute care syndromic testing market?
North America was the largest region in the acute care syndromic testing market in 2024. The regions covered in the acute care syndromic testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Anthrax Vaccine Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/anthrax-vaccine-global-market-report
Dendritic Cell Cancer Vaccine Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/dendritic-cell-cancer-vaccine-global-market-report
Cell and Gene Therapy Global Market Report 2025
https://thebusinessresearchcompany.com/report/cell-and-genes-therapy-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
